Samsung Bioepis Achieves Ophthalmology Milestone With Korean Aflibercept Approval
SB15 Biosimilar To Eylea Approved Shortly After Firm Agreed Marketing Deal With Samil
• By David Wallace
Samsung Bioepis has become the first developer with approvals for both Lucentis and Eylea biosimilars • Source: Shutterstock 
